Interventional and Structural Cardiologist @GaHeart_NGHS || Trained @MGHHeartHealth || Former IM Resident / Chief Resident at Emory SOM and Grady
Atlanta, Georgia
Joined March 2013
- Tweets146
- Following517
- Followers771
- Likes679
Marc Allard-Ratick retweeted
Can LAAC replace DOACs for #stroke prevention in #AFib?
New in #JACCAdvances: This meta-analysis of randomized trials found LAAC reduced nonprocedure-related bleeding but may come at the cost of a higher risk of ischemic stroke. jacc.org/doi/10.1016/j.jacad…
#NOAC #cvLAAOccluder
Marc Allard-Ratick retweeted
I was up last night with a STEMI until 4:30. For my entire career I’ve gone to work the next day with whatever sleep I could get. Not anymore. Today, I slept in and did chart work from home. You can’t fly an airplane or drive a truck if you’ve been up all night. Why should it be different for docs?
Marc Allard-Ratick retweeted
Hemodynamic performance of self-expanding transcatheter valve superior to balloon-expandable valve for small VIV-TAVR for failed small surgical aortic bioprosthesis. The 3-Year Results of the LYTEN Trial @PPibarot @luisnombela @ENofrerias @victoria_vilata ahajrnls.org/4kg2ibS
Marc Allard-Ratick retweeted
(1/2) Our study in @JACCJournals uses causal inference techniques to show that after @usnews TAVR ratings were released in 2020 there was a significant decline in the # of high risk AS patients receiving TAVR driven by lower rated hospitals.
jacc.org/doi/abs/10.1016/j.j…
Marc Allard-Ratick retweeted
Just published: Beyond Limits in Alternative Access: The Success of Right Subclavian Transcatheter Mitral Valve Replacement
sciencedirect.com/science/ar…
@Brianponeill @PedroMDMSc @engelpedro @GKFram @AhmadJabri8
Marc Allard-Ratick retweeted
First-in-human percutaneous transseptal Retrieveal of Embolized TRanscatheter valve In the lEft VEntricle (RETRIEVE)
Now in press in JACC CVI
Thank you to the patient/family and the Morristown team for the trust and support in me for this great save.
@PhilGenereuxMD
Marc Allard-Ratick retweeted
Interventional cardiologists with Georgia Heart Institute recently performed the first cases in the Southern United States using the SpectraWAVE HyperVue Imaging System. This system uses near-infrared "DeepOCT" and NIRS technology to capture highly detailed images from inside the coronary arteries. These images, powered by AI, help cardiologists make better-informed decisions to treat their patients. Kudos to Dr. Glen Henry, Dr. Stephane Rinfret and Dr. Olga Toleva and their team for bringing the future of heart care to our community — today! Learn more about our interventional cardiology program: nghs.com/heart/interventiona…
Marc Allard-Ratick retweeted
Braunwald reverses 35 year old stance in asymptomatic severe aortic stenosis &AVR
bit.ly/3EBr0Tt
Don’t wait for symptoms to develop in severe AS!
No more “watchful waiting”
#justdoit Act & send patient for TAVR or SAVR @JAMACardio
Marc Allard-Ratick retweeted
LAMPOON enabled #TMVR despite the risk for #LVOT obstruction. There were no long-term complications assoc w/ LAMPOON. The selection of inoperable pts limited assessment of long-term survival following TMVR bit.ly/4h6fH4H
#JACCINT @TheBethesdaLabs @CathElectroSurg @AdamGreenbaumMD @BabaliarosArgos @jamiemccabeMD
Marc Allard-Ratick retweeted
Does Sentinel @BSCCardiology reduce disabling stroke during #TAVR ?
✅YES, but benefit is small (13% RRR; NNT ~500-800) for all comers.
✅Patients with prior stroke have a ⬆️⬆️ benefit (RRR 40%, NNT ~150).
LBCS @crfheart #NYValves2024 with sim pub @CircIntv
Thread ⬇️
Marc Allard-Ratick retweeted
📖The novel balloon-assisted double-kissing T-stenting #DKT for the treatment of complex #coronary #bifurcation: concept, in vitro model, & case examples. #PCI #CHIP🔎
➡️doi.org/10.1016/j.jscai.2024…
@RinfretStephane @kevinjamescroce @lvjulien_md
Marc Allard-Ratick retweeted
Astonishing results from the DanGer Shock Trial presented at #ACC24 and out in @NEJM today.
In patients with ST-elevation MI with cardiogenic shock, Impella reduced all-cause mortality (45.8% Impella vs. 58.5% control) at 180 days.
Some thoughts on this ground breaking trial:
Marc Allard-Ratick retweeted
The first case in our series of percutaneously removed mitraclips followed by TMVRs now published in JACC Int.
sciencedirect.com/science/ar…
Marc Allard-Ratick retweeted
The mitral valve (anterior leaflet) is designed to direct blood flow towards a smooth sliding path which begins at the basal posterior wall and ends at the LVOT—thereby minimizing LV energy expenditure during ejection.
Cheers🍷
Marc Allard-Ratick retweeted
Can we precisely rewrite the genetic code - make a single DNA spelling change - in the liver of a human being for clinical effect?
YES!
Scientific milestone: VERVE-101 provides first proof-of-concept for in vivo DNA base editing in humans
Clinical implication: It’s early but could open the way for an entire new way to treat heart disease; instead of daily pills/intermittent injections, a one-time intravenous infusion procedure to durably (possibly lifelong) lower LDL cholesterol; "surgery without a scalpel"
Takeaways:
1. 10 patients with severe HeFH and ASCVD treated so far across 4 dose levels
2. Clinical effect on LDL-C (40% - 55% reductions) at potentially therapeutic doses
3. Dose-dependent reductions in blood PCSK9 protein and blood LDL-C
4. Durability so far out to six months, consistent with the pre-clinical data in NHP where the durability is out to 2.5y after a single treatment
5. Consistent with FDA guidance on patients to enroll in a Phase 1 study of gene editing products, we enrolled the sickest of the sick coronary disease patients
6. Safety profile revealed expected LNP-infusion related events: a) transient flu-like symptoms for a few hours after infusion; b) transient, reversible rise in LFTs after infusion
7. Two patients experienced CV events consistent with their underlying severe ASCVD
8. Safety profile supports continued development (DSMB have reviewed these data and requested to continue dosing)
9. These interim heart-1 data were submitted to FDA as part of IND package and we now have clearance to start study in U.S.
10. Next steps: finish dose escalation, complete dose expansion in 2024
11. Phase 2 start in 2025 for PCSK9 program
Foremost, grateful to the patients who have volunteered and their families
Thankful to the amazing @VerveTx scientific and clinical team (led by @andrew Bellinger), the investigators and study staff, the independent DSMB, and our partners
P.S. Deepavali celebrates new knowledge and so thrilled to add today to our knowledge on the intersection of gene editing technology and cardiovascular disease
$VERV
@AHAScience @AHAMeetings @American_Heart #AHA23
Marc Allard-Ratick retweeted
Thank you @UWCathLab and @DrBillLombardi for having me as a live case operator. Outstanding cases and fantastic learning!
Special shout out to my co-operators, @KateKearney4 and @RhianEDavies1!
Looking forward to even more collaboration with @UWMedHeart and @MGHHeartHealth.
Marc Allard-Ratick retweeted
Long-Term Outcome of Drug-Coated Balloon vs Drug-Eluting Stent for Small Coronary Vessels: PICCOLETO-II 3-Year Follow-Up: @JACCJournals
The promise of drug coated balloons for small vessels (2 to 2.75mm)!
Summary 👇👇👇
Marc Allard-Ratick retweeted
Provisional is the most adopted #bifurcation #stenting strategy: which ballooning sequence provides better post- #PCI #OCT result?
First pt randomized by our team in CRABBIS trial (ClinicalTrials.gov Identifier:NCT05559424) comparing POT-SIDE-POT vs. POT-KISS-POT
Marc Allard-Ratick retweeted
First in human use of the @ONOCORvascular nitinol basket retrieval system, the Ono, to remove a percutaneously excised right atrial myxoma (more on that in a moment). Worked great! with @ZLSteinberg & @DavidElison1
